AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Editas Medicine Inc. (EDIT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.73

0.35 (25.36%)

At close: Feb 18, 2025, 3:59 PM

1.77

2.61%

After-hours: Feb 18, 2025, 06:31 PM EST

undefined% (undefined)

Bid	1.74
Market Cap	142.40M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.54
PE Ratio (ttm)	-0.68
Forward PE	n/a
Analyst	Hold

Ask	1.78
Volume	9,055,560
Avg. Volume (20D)	2,708,601
Open	1.42
Previous Close	1.38
Day's Range	1.42 - 1.76
52-Week Range	1.12 - 11.58
Beta	undefined

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 3, 2016

Employees 265

Stock Exchange NASDAQ

Ticker Symbol EDIT

Website https://www.editasmedicine.com

Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for EDIT stock is "Hold." The 12-month stock price forecast is $7.5, which is an increase of 334.78% from the latest price.

Buy 42.86%

Hold 42.86%

Sell 7.14%

Stock Forecasts

Next Earnings Release

Editas Medicine Inc. is scheduled to release its earnings on Mar 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-23.81%

Editas Medicine shares are trading lower after Sti... Unlock content with Pro Subscription

2 months ago

-5.03%

Editas Medicine shares are trading higher after the company announced plans to transition to an in vivo focus and initiated a reduction in headcount, aiming to eliminate approximately 65% of its workforce over the next six months.

News

1 month ago · seekingalpha.com

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despi...

1 month ago · seekingalpha.com

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Editas Medicine, Inc. (NASDAQ:EDIT ) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Linda Burk...

2 months ago · zacks.com

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

2 months ago · benzinga.com

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

On Thursday, Editas Medicine Inc. EDIT announced a strategic realignment to focus on in vivo gene editing.

2 months ago · reuters.com

Editas to reduce about 65% of its workforce over the next six months

Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies...

2 months ago · zacks.com

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, reni-cel, for severe SCD.

2 months ago · zacks.com

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

2 months ago · seekingalpha.com

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Editas Medicine, Inc. (NASDAQ:EDIT ) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Erick Lucera - Executive Vice President and Chief Financial Officer Cris...

2 months ago · benzinga.com

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

BofA Securities downgraded Editas Medicine Inc EDIT, citing few value-driving catalysts in the near term.

3 months ago · seekingalpha.com

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Editas Medicine, Inc. (NASDAQ:EDIT ) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha ...